BELLUS Health Inc BLUSD

Primary Symbol: T.BLU

Healthcare Biotechnology

BELLUS Health Inc. is a clinical-stage biopharmaceutical company developing therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. The Company's lead product candidate, BLU-5937, which is a selective, small molecule antagonist of the P2X3 receptor, as an oral therapy to reduce cough frequency in RCC patients. The Company has completed the BLUEPRINT clinical trial, a Phase II trial evaluating BLU-5937 in patients with chronic pruritus associated with AD. The Company is focused on initiating Phase III program. The Company is exploring the use of BLU-5937 in other patient populations experiencing cough hypersensitivity as well as other P2X3-related hypersensitization conditions.

TSX:BLU - Post by User

BELLUS Health Inc

Bullboard Posts

Comment by Atomekon Mar 02, 2018 1:31pm

164 Views

Post# 27652693

RE:volume

Trades for C:BLU on 20180301 for broker #62 - 11 trades displayed

Time ET	Ex	Price	Change	Volume	Buyer	Seller	Markers
15:56:24	T	0.41		3,500	62 Haywood	9 BMO Nesbitt	K
15:44:38	U	0.41		2,500	62 Haywood	2 RBC	K
15:44:38	T	0.41		500	62 Haywood	2 RBC	K
15:44:38	T	0.41		30,000	62 Haywood	9 BMO Nesbitt	K
15:44:38	T	0.41		2,500	62 Haywood	124 Questrade	K
15:44:38	T	0.41		2,500	62 Haywood	124 Questrade	K
15:44:38	T	0.41		5,000	62 Haywood	2 RBC	K
15:44:38	T	0.41		6,500	62 Haywood	19 Desjardins	K
15:44:38	T	0.41		6,000	62 Haywood	9 BMO Nesbitt	K
15:44:37	T	0.41		217	62 Haywood	62 Haywood
15:44:37	T	0.41		9,209,000	62 Haywood	62 Haywood	K